BRPI0818165B8 - método de produção recombinante de uma imunoglobulina heteróloga em células cho que é secretada para o meio de cultura - Google Patents

método de produção recombinante de uma imunoglobulina heteróloga em células cho que é secretada para o meio de cultura

Info

Publication number
BRPI0818165B8
BRPI0818165B8 BRPI0818165A BRPI0818165A BRPI0818165B8 BR PI0818165 B8 BRPI0818165 B8 BR PI0818165B8 BR PI0818165 A BRPI0818165 A BR PI0818165A BR PI0818165 A BRPI0818165 A BR PI0818165A BR PI0818165 B8 BRPI0818165 B8 BR PI0818165B8
Authority
BR
Brazil
Prior art keywords
nucleic acid
selection agent
cell
culture medium
heterologous immunoglobulin
Prior art date
Application number
BRPI0818165A
Other languages
English (en)
Inventor
Stern Anne
Kopetzki Erhard
Knoetgen Hendrik
Goepfert Ulrich
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39204855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0818165(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0818165A2 publication Critical patent/BRPI0818165A2/pt
Publication of BRPI0818165B1 publication Critical patent/BRPI0818165B1/pt
Publication of BRPI0818165B8 publication Critical patent/BRPI0818165B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

método de produção recombinante de uma imunoglobulina heteróloga em células cho que é secretada para o meio de cultura, anti-abeta, antisseleção p, anti-il-13ralfa, bem como conjugado de anticorpo anticd4. a presente invenção refere-se a um método para a produção recombinante de uma imunoglobulina heteróloga secretada em uma célula cho, compreendendo as seguintes etapas: i) proporcionar uma célula cho, a qual está adaptada ao crescimento em cultura em suspensão, adaptada ao crescimento em meio sem soro, sem micoplasma, e sem vírus, ii) proporcionar um vetor compreendendo uma origem de replicação procariótica, um primeiro ácido nucleico conferindo resistência a um agente de seleção procariótico, um segundo ácido nucleico codificando a cadeia longa da dita imunoglobulina heteróloga, um terceiro ácido nucleico codificando a cadeia curta da dita imunoglobulina heteróloga, um quarto ácido nucleico conferindo resistência a um agente de seleção eucariótico, iii) transfectar a dita célula cho, em que a dita transfecção compreende a) transfectar a dita célula cho com o dito vetor compreendendo um quarto ácido nucleico conferindo resistência a um primeiro agente de seleção eucariótico, b) selecionar uma célula cho por crescimento em um meio de cultivo contendo o dito primeiro agente de seleção eucariótico, c) transfectar a dita célula cho selecionada com o dito vetor compreendendo um quarto ácido nucleico conferindo resistência a um segundo agente de seleção eucariótico diferente do dito primeiro agente de seleção eucariótico, d) selecionar uma célula cho por crescimento selecionado em um meio de cultivo contendo o dito primeiro e o dito segundo agentes de seleção eucarióticos, iv) cultivar a dita célula cho transfectada em um meio na presença dos ditos primeiro e segundo agentes de seleção eucarióticos, sob condições adequadas para a expressão dos ditos segundo e terceiro ácidos nucleicos, e v) recuperar a dita imunoglobulina heteróloga secretada do meio de cultivo.
BRPI0818165A 2007-10-12 2008-10-09 método de produção recombinante de uma imunoglobulina heteróloga em células cho que é secretada para o meio de cultura BRPI0818165B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07019999 2007-10-12
EP07019999.7 2007-10-12
PCT/EP2008/008523 WO2009046978A1 (en) 2007-10-12 2008-10-09 Protein expression from multiple nucleic acids

Publications (3)

Publication Number Publication Date
BRPI0818165A2 BRPI0818165A2 (pt) 2014-10-14
BRPI0818165B1 BRPI0818165B1 (pt) 2020-10-27
BRPI0818165B8 true BRPI0818165B8 (pt) 2021-05-25

Family

ID=39204855

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0818165A BRPI0818165B8 (pt) 2007-10-12 2008-10-09 método de produção recombinante de uma imunoglobulina heteróloga em células cho que é secretada para o meio de cultura
BRPI0818536-0A2A BRPI0818536A2 (pt) 2007-10-12 2008-10-13 Linhagem celular cho-k1

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0818536-0A2A BRPI0818536A2 (pt) 2007-10-12 2008-10-13 Linhagem celular cho-k1

Country Status (20)

Country Link
US (5) US8771988B2 (pt)
EP (4) EP2592148B1 (pt)
JP (2) JP5642549B2 (pt)
KR (2) KR101280704B1 (pt)
CN (2) CN101815786A (pt)
AU (2) AU2008309934B2 (pt)
BR (2) BRPI0818165B8 (pt)
CA (2) CA2701646C (pt)
DK (1) DK2592148T3 (pt)
ES (1) ES2695999T3 (pt)
HR (1) HRP20181833T1 (pt)
HU (1) HUE039950T2 (pt)
IL (2) IL203902A0 (pt)
LT (1) LT2592148T (pt)
MX (3) MX2010003622A (pt)
PL (1) PL2592148T3 (pt)
PT (1) PT2592148T (pt)
SI (1) SI2592148T1 (pt)
TR (1) TR201816045T4 (pt)
WO (2) WO2009046978A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG177247A1 (en) * 2009-06-11 2012-02-28 Kek High Energy Accelerator Process for production of protein
DK2517556T4 (da) * 2009-07-08 2023-05-15 Kymab Ltd Fremgangsmåde til punkt-specifik rekombination, gnavere og gnaverceller i stand til at udtrykke kimære antistoffer eller kæder
RU2017138926A (ru) 2009-08-11 2019-02-11 Дженентек, Инк. Получение белков в культуральных средах без глутамина
EP2524041A4 (en) * 2009-11-16 2013-08-07 Acyte Biotech Pty Ltd RECOMBINANT ANTIBODY VECTOR
US9096879B2 (en) * 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
US8986957B2 (en) 2010-04-26 2015-03-24 Novartis Ag Cell culture medium
US9068198B2 (en) 2010-09-15 2015-06-30 Medimmune Limited Chinese hamster ovary cell line
EP2635607B1 (en) 2010-11-05 2019-09-04 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
CA2846319A1 (en) 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
RU2675319C2 (ru) 2011-11-04 2018-12-18 Займворкс Инк. РАЗРАБОТКА СТАБИЛЬНОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В ДОМЕНЕ Fc
SG11201403223PA (en) 2011-12-22 2014-07-30 Hoffmann La Roche Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
EP2674495A1 (en) * 2012-06-14 2013-12-18 Sanofi CHO expression system
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
CN110951670A (zh) 2013-03-15 2020-04-03 豪夫迈·罗氏有限公司 具有抗氧化剂的细胞培养组合物和多肽生产方法
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
EP3794941B1 (en) 2013-10-01 2024-09-25 Kymab Limited Animal models and therapeutic molecules
US10947319B2 (en) 2013-11-27 2021-03-16 Zymeworks Inc. Bispecific antigen-binding constructs targeting HER2
WO2015148515A1 (en) * 2014-03-24 2015-10-01 Biogen Ma Inc. Methods for overcoming glutamine deprivation during mammalian cell culture
KR102603417B1 (ko) 2014-05-06 2023-11-20 제넨테크, 인크. 포유동물 세포를 사용한 이종다량체 단백질의 생산
JP6333378B2 (ja) * 2014-07-16 2018-05-30 Ｈｅａｒｔｓｅｅｄ株式会社 新規未分化幹細胞除去および心筋純化精製培地
CN113981027A (zh) * 2015-04-27 2022-01-28 动量制药公司 制备治疗性蛋白质的方法
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
JP6937309B2 (ja) 2016-01-27 2021-09-22 ジャスト−エヴォテック バイオロジックス、インコーポレイテッド ハイブリッドプロモーターおよびその使用
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
MX2018012470A (es) 2016-04-15 2019-07-01 Alder Biopharmaceuticals Inc Anticuerpos anti pacap humanizados y usos de ellos.
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
GB201718088D0 (en) * 2017-11-01 2017-12-13 Autolus Ltd Vectors
CN111019881B (zh) * 2019-11-21 2020-10-09 中山康天晟合生物技术有限公司 一种适应高渗透压、高铵离子、高乳酸生长环境的细胞
BR112022021203A2 (pt) 2020-04-24 2022-12-06 Hoffmann La Roche Modulação de enzima e via com compostos sulfidrila e seus derivados
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
CN112920995A (zh) * 2021-03-31 2021-06-08 赵峻岭 一种间充质干细胞培养血清加油包及其应用
CN115521919B (zh) * 2022-11-04 2023-04-11 广州誉衡生物科技有限公司 一种调节pd-1抗体和lag-3抗体酸性电荷异构体的cho细胞培养方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912038A (en) 1984-12-11 1990-03-27 California Biotechnology Inc. Recombinant DNA sequence encoding alveolar surfactant protein
DE3688418T2 (de) 1985-02-13 1993-08-26 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
AU2263288A (en) 1987-07-16 1989-02-13 Codon Transfected cells containing plasmids having genes oriented in opposing directions and methods of obtaining the same
CA1341235C (en) * 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
EP0319206A3 (en) 1987-11-30 1990-04-18 Berlex Laboratories, Inc. Gene amplification
WO1989010959A1 (en) 1988-05-06 1989-11-16 Codon Supertransformants for high expression rates in eukaryotic cells
DD287531A5 (de) 1988-06-16 1991-02-28 Akademie Der Wissenschaften,De Verfahren zur herstellung von humanem wachstumshormon (sth) in tierischen zellen
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
JP2859679B2 (ja) * 1990-03-01 1999-02-17 協和醗酵工業株式会社 新規細胞株
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
GB9114468D0 (en) * 1991-07-04 1991-08-21 Wellcome Found Antibody production
EP0569678A3 (en) 1992-03-13 1994-10-26 Yeda Res & Dev Double transfectants of MHC genes as cellular vaccines for immunoprevention of tumor metastasis.
US5420019A (en) 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
WO1994025067A1 (en) * 1993-05-04 1994-11-10 Cytel Corporation Antibodies to p-selectin and their uses
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
SG48813A1 (en) 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
WO1995017513A1 (en) * 1993-12-23 1995-06-29 Novo Nordisk A/S Retransformation of filamentous fungi
US5719050A (en) * 1993-12-24 1998-02-17 Eiken Chemical Co., Ltd. Animal cell culturing media containing N-acetyl-L-glutamic acid
US5726041A (en) 1995-08-30 1998-03-10 Gentest Corporation Method for detecting a receptor-ligand complex using a cytochrome P450 reporter gene
EP2218775B1 (en) 1996-08-30 2015-01-28 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
WO1998033523A1 (en) 1997-01-31 1998-08-06 Biovation Limited Vaccination methods and molecules
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
CA2310987A1 (en) 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
AU2767999A (en) * 1998-03-18 1999-10-11 Pharmacopeia, Inc. Eukaryotic cells stably expressing genes from multiple transfected episomes
BR9905867A (pt) 1998-11-06 2001-01-23 Bio Sidus S A Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula
TW570977B (en) 1998-12-07 2004-01-11 Li-Wei Hsu An expression system for producing recombinant human erythropoietin, method for purifying secreted human erythropoietin and uses thereof
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
DE19920712A1 (de) 1999-05-05 2000-11-09 Rhein Biotech Proz & Prod Gmbh Verfahren zum Herstellen eines rekombinanten Proteines
EP1210411B1 (en) * 1999-08-25 2006-10-18 Immunex Corporation Compositions and methods for improved cell culture
AUPQ422399A0 (en) 1999-11-24 1999-12-16 University Of New South Wales, The Method of screening transformed or transfected cells
DE10036491A1 (de) * 2000-07-25 2002-02-07 Roche Diagnostics Gmbh Expression von Alkalischer Phosphatase in Hefe
HUP0500059A2 (hu) 2001-11-28 2005-04-28 Sandoz Ag. Eljárás rekombináns polipeptid előállítására
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
WO2003076588A2 (en) 2002-03-05 2003-09-18 Vitra Bioscience, Inc. Multiplexed cell transfection using coded carriers
DE10213201A1 (de) 2002-03-25 2003-10-16 Roche Diagnostics Gmbh Erzeugung von schwach aktiven oder inaktiven Mutanten von Alkalischer Phosphatase und deren Expression in Hefe
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
WO2004087758A2 (en) 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
WO2005113770A1 (en) 2004-05-13 2005-12-01 Institut Gustave Roussy Anti-rhoa and -rhoc sirnas and therapeutic compositions comprising them.
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
DE102005046225B4 (de) * 2005-09-28 2012-01-05 Cellca Gmbh Verbessertes Zellkulturmedium
TW200722436A (en) 2005-10-21 2007-06-16 Hoffmann La Roche A peptide-immunoglobulin-conjugate
US20070218062A1 (en) 2006-03-16 2007-09-20 Genentech, Inc. Methods of treating lupus using CD4 antibodies
CN103539857A (zh) * 2006-03-30 2014-01-29 葛兰素集团有限公司 针对β-淀粉样蛋白肽的抗体
AR067584A1 (es) 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos

Also Published As

Publication number Publication date
CA2701677A1 (en) 2009-04-16
EP2592148B1 (en) 2018-09-12
SI2592148T1 (sl) 2018-12-31
IL203900A0 (en) 2011-07-31
MX338036B (es) 2016-03-31
BRPI0818165A2 (pt) 2014-10-14
EP2592148A1 (en) 2013-05-15
CN101821394A (zh) 2010-09-01
IL203902A0 (en) 2011-07-31
BRPI0818536A2 (pt) 2014-10-14
EP2592147A1 (en) 2013-05-15
US8771988B2 (en) 2014-07-08
US20100249379A1 (en) 2010-09-30
PL2592148T3 (pl) 2019-01-31
CA2701646C (en) 2019-02-26
CA2701646A1 (en) 2009-04-16
KR101280704B1 (ko) 2013-07-01
US20190233842A1 (en) 2019-08-01
JP5642549B2 (ja) 2014-12-17
LT2592148T (lt) 2018-12-10
AU2008309934A1 (en) 2009-04-16
ES2695999T3 (es) 2019-01-11
MX2010003620A (es) 2010-04-14
US9428766B2 (en) 2016-08-30
CN101815786A (zh) 2010-08-25
JP2011500009A (ja) 2011-01-06
WO2009046978A1 (en) 2009-04-16
US20140335609A1 (en) 2014-11-13
US20100221781A1 (en) 2010-09-02
EP2207881A1 (en) 2010-07-21
HUE039950T2 (hu) 2019-02-28
DK2592148T3 (en) 2018-12-10
WO2009047007A1 (en) 2009-04-16
HRP20181833T1 (hr) 2019-01-11
KR20100059967A (ko) 2010-06-04
EP2207882A1 (en) 2010-07-21
IL203900A (en) 2014-08-31
AU2008309934B2 (en) 2014-03-06
US20170166923A1 (en) 2017-06-15
BRPI0818165B1 (pt) 2020-10-27
PT2592148T (pt) 2018-11-12
MX2010003622A (es) 2010-04-14
JP2010540583A (ja) 2010-12-24
TR201816045T4 (tr) 2018-11-21
AU2008309881A1 (en) 2009-04-16
KR20100059969A (ko) 2010-06-04

Similar Documents

Publication Publication Date Title
BRPI0818165B8 (pt) método de produção recombinante de uma imunoglobulina heteróloga em células cho que é secretada para o meio de cultura
AU2019268194A1 (en) Cell culture system
Liu et al. Development of a new method for genetic transformation of the green alga Chlorella ellipsoidea
Cabanelas et al. Sorting cells of the microalga Chlorococcum littorale with increased triacylglycerol productivity
BRPI0922572A2 (pt) método para cultivar células pluripotentes, cultura de células de mamífero pluripotentes, meio de cultura de célula, célula animal pluripotente isolada, e, método para aumentar a pluripotência de uma célula de mamífero.
BR112014006244A2 (pt) microrganismos e métodos para produzir alcenos
MY156588A (en) Systems using cell culture for production of isoprene
EP3147363A3 (en) Activation of taste receptor genes in mammalian cells using crispr-cas-9
BR112015022971A2 (pt) métodos de fabricação para controlar o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes
BR112013028621A2 (pt) "microalgas oleaginosas recombinantes, método para produzir biomassa de microalga ou um produto produzido da biomassa, e método para produzir uma composição lipídica de microalga".
EA201490631A1 (ru) Способы культивирования клеток млекопитающих для получения белка
UY32066A (es) Construcciones de adn recombinante y métodos para modular la expresión de un gen diana
JP2015521848A5 (pt)
Kang et al. Heterologous overexpression of sfCherry fluorescent protein in Nannochloropsis salina
BR112013020217A2 (pt) método e biorreator para o cultivo de micro-organismos
BRPI0906241B8 (pt) molécula de ácido nucleico, gene quimérico, vetor e método de transformação de uma célula bacteriana
EP4061941A1 (en) Retrotransposons and use thereof
BR112012031965A2 (pt) uso de promotores induzíveis na produção de ácido glicórico.
BRPI1008762B8 (pt) métodos para seleção de células de mamífero expressando uma proteína heteróloga, para produzir um produto de interesse e uso de um meio de cultura seletivo
Bauer et al. 1 ARGININE SUPPLEMENTATION IN VITRO INCREASES PORCINE EMBRYO DEVELOPMENT AND AFFECTSmRNA TRANSCRIPT EXPRESSION
BR112015012408A2 (pt) célula somática geneticamente modificada, método para produzir um animal não humano, e, ovócito clonado de um animal não humano
Ciesielski et al. Nucleoid localization of Hsp40 Mdj1 is important for its function in maintenance of mitochondrial DNA
Ito et al. Development of a versatile method for targeted gene deletion and insertion by using the pyrF gene in the psychrotrophic bacterium, Shewanella livingstonensis Ac10
BR112013028006A2 (pt) método para aumentar a produtividade de células eucarióticas na produção do recombinante fviii
WO2011056886A3 (en) Method and composition for generating programmed cell death resistant algal cells

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF